Abstract
The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. Laboratory, epidemiological, and clinical studies have surged and continued to evaluate and understand the safety of coxibs and traditional NSAIDs. This paper reviews the scientific and clinical basis of not only the risks, but also the benefits surrounding the use COX-2 inhibitors and NSAIDs. Discussion, debate, opinions, regulatory and clinical recommendations have evolved since the unexpected emergence of cardiac thrombotic events from the use of these drugs. The evidence by which coxibs and NSAIDs can potentially attenuate or exacerbate cardiovascular disease by affecting endothelial function is assessed; and how NSAIDs and coxibs affect renal function and blood pressure is revisited. Several investigations provide insight into their mechanism and clinical application.
Keywords: COX-2 inhibition, COX-blockade, NSAIDs, coxibs, COX-2 selective inhibitor, COX-2 specific inhibitor, endothelial dysfunction, gastrointestinal toxicity
Current Drug Safety
Title: Risk-Benefit Perspectives in COX-2 Blockade
Volume: 3 Issue: 1
Author(s): Susan Dabu-Bondoc and Samantha Franco
Affiliation:
Keywords: COX-2 inhibition, COX-blockade, NSAIDs, coxibs, COX-2 selective inhibitor, COX-2 specific inhibitor, endothelial dysfunction, gastrointestinal toxicity
Abstract: The withdrawal of the celebrity arthritis drug, rofecoxib (Vioxx) has sparked an intense discussion and controversy about the safety of the selective COX-2 inhibitors. Laboratory, epidemiological, and clinical studies have surged and continued to evaluate and understand the safety of coxibs and traditional NSAIDs. This paper reviews the scientific and clinical basis of not only the risks, but also the benefits surrounding the use COX-2 inhibitors and NSAIDs. Discussion, debate, opinions, regulatory and clinical recommendations have evolved since the unexpected emergence of cardiac thrombotic events from the use of these drugs. The evidence by which coxibs and NSAIDs can potentially attenuate or exacerbate cardiovascular disease by affecting endothelial function is assessed; and how NSAIDs and coxibs affect renal function and blood pressure is revisited. Several investigations provide insight into their mechanism and clinical application.
Export Options
About this article
Cite this article as:
Dabu-Bondoc Susan and Franco Samantha, Risk-Benefit Perspectives in COX-2 Blockade, Current Drug Safety 2008; 3 (1) . https://dx.doi.org/10.2174/157488608783333970
DOI https://dx.doi.org/10.2174/157488608783333970 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Mechanisms Involved in Metformin Action in the Treatment of Polycystic Ovary Syndrome
Current Pharmaceutical Design Acute and Subacute Toxicity Study on Dietary Supplementation with Soy Isoflavones in Wistar Rats
Current Nutrition & Food Science Regulation of Neurogenesis and Angiogenesis in Depression
Current Neurovascular Research Obesity and Pregnancy
Current Women`s Health Reviews The Metabolic Treatment of Patients with Coronary Artery Disease: Effects on Quality of Life and Effort Angina
Current Pharmaceutical Design Heat Shock Proteins: Mediators of Atherosclerotic Development
Current Drug Targets Epigenetics: New Concepts of Old Phenomena in Vascular Physiology
Current Vascular Pharmacology The Effects of Obesity-Related Peptides on the Vasculature
Current Vascular Pharmacology Serum Uric Acid and Diabetes: From Pathophysiology to Cardiovascular Disease
Current Pharmaceutical Design Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Linezolid Induced Skin Reactions in a Multi Drug Resistant Infective Endocarditis Patient: A Rare Case
Current Drug Safety Pharmacological Interventions on Asymmetric Dimethylarginine, a Clinical Marker of Vascular Disease
Current Medicinal Chemistry Smoking and Cardiovascular System: Cellular Features of the Damage
Current Pharmaceutical Design Stroke Risk Stratification Schemes in Atrial Fibrillation in the Era of Non- Vitamin K Anticoagulants: Misleading and Obsolete, At Least for the “Low-Risk” Patients?
Current Drug Targets Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Inflammation-Mediating Proteases: Structure, Function in (Patho) Physiology and Inhibition
Protein & Peptide Letters Pulmonary Hypertension secondary to Left Heart Disease
Current Vascular Pharmacology Phase 4 Studies in Heart Failure - What is Done and What is Needed?
Current Cardiology Reviews Intracardiac Origin of Heart Rate Variability, Pacemaker Funny Current and their Possible Association with Critical Illness
Current Cardiology Reviews